Fight over “pay for delay” heats up in Washington July 22, 2021 Auto Bot BioPharma, biopharma nl, Biosimilar, Legal, News, Pharma, Policy 0 Legislators threaten to ban settlements where branded companies “pay” generics makers to “delay” market entry, while drugmakers say the current framework balances competition and innovation. Who will prevail?